|
Market Closed -
Börse Stuttgart
05:55:41 26/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 0.001500 EUR | 0.00% |
|
0.00% | -25.00% |
| 22/09 | WINNERS & LOSERS: Petro Matad sinks on PetroChina blow; Midwich up | AN |
| 14/09 | WINNERS & LOSERS: Tribal to sell assets; Brave Bison ups System1 tilt | AN |
| Market Cap | 3.52M 4.66M 4.09M 3.87M 6.6M 447M 6.64M 46.26M 17.92M 228M 17.51M 17.14M 734M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.43M 4.54M 3.98M 3.76M 6.41M 435M 6.46M 44.98M 17.42M 222M 17.03M 16.66M 714M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
Börse StuttgartEUR
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 21/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 21/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| Current month | +50.00% | ||
| 3 months | +200.00% | ||
| 6 months | +50.00% | ||
| Current year | -25.00% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| 3 years | 0 | | 0 |
| 5 years | 0 | | 0.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 01/07/2022 |
| Director/Board Member | 61 | 02/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 01/09/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | +50.00% | -25.00% | 4.45M | |
| +0.13% | +2.69% | +59.53% | +114.96% | 1,053B | |
| +0.20% | +0.37% | +53.50% | +68.98% | 652B | |
| -0.29% | +0.12% | +20.16% | +73.07% | 468B | |
| -0.85% | -0.25% | +38.63% | +44.47% | 351B | |
| +0.71% | +3.26% | +22.46% | +30.30% | 273B | |
| +1.23% | +1.00% | +11.97% | +13.63% | 254B | |
| +2.11% | +9.17% | +48.49% | +54.88% | 220B | |
| +0.83% | +0.03% | +32.78% | +101.21% | 186B | |
| 0.00% | -9.43% | -31.91% | -60.56% | 170B | |
| Average | +0.39% | +0.32% | +30.56% | +41.60% | 403.04B | |
| Weighted average by Cap. | +0.27% | +1.01% | +38.89% | +68.42% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.82M -4.23M -4M -6.82M -462M -6.87M -47.82M -18.52M -236M -18.1M -17.71M -759M | -653K -864K -758K -716K -1.22M -82.81M -1.23M -8.57M -3.32M -42.31M -3.24M -3.17M -136M |
| Net Debt | -20.21K -26.76K -23.48K -22.18K -37.83K -2.56M -38.1K -265K -103K -1.31M -100K -98.3K -4.21M | -97.55K -129K -113K -107K -183K -12.38M -184K -1.28M -496K -6.32M -485K -474K -20.33M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 26/09/26 | EUR 0.001500 | 0.00% |
| 24/09/26 | EUR 0.001500 | 0.00% |
| 23/09/26 | EUR 0.001500 | +50.00% |
| 22/09/26 | EUR 0.001000 | 0.00% |
| 21/09/26 | EUR 0.001000 | -33.33% |
- Stock Market
- Stocks
- LVRT Stock
- 1RT Stock
Select your edition
All financial news and data tailored to specific country editions
